> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# MASLD fibrosis screening with sequential ELF testing and health equity in US veterans
- URL: https://www.coios.me/masld-fibrosis-screening-with-sequential-elf-testing-and/
- Published: 2026-11-22T13:08:55.000Z
- Updated: 2026-11-22T13:53:58.000Z
- Description: An ELF blood test after an indeterminate FIB-4 score cost screened veterans health but gave the largest net population gain.
- Author: Daniel Ryan
- Tags: Data, models and systems, Value in health, United States, #peer-reviewed, #new, #item, #source-2026-11, #score-68

This distributional cost-effectiveness analysis compared six MASLD fibrosis screening strategies in 15 veteran subgroups defined by race/ethnicity and social vulnerability. One strategy added an Enhanced Liver Fibrosis (ELF) blood test for indeterminate FIB-4 scores, referring those scoring above 9.80\. Against standard FIB-4 screening, it cut referrals and treatment, costing screened veterans 91,370 QALYs. Counting its savings as health elsewhere at $100,000 per QALY gave the largest net gain, 185,010 QALYs. It also gave the largest fall in health inequality on the Atkinson index (0.112%). Results depended on how much of the savings was assumed to become health for other patients.

*Why it is interesting: ELF screening at a lower 9.00 cutoff gave screened veterans the largest direct gains. It was not preferred once health forgone elsewhere and distributional effects were counted.*

Source

[PharmacoEconomics, 20 November 2026](https://doi.org/10.1007/s40273-026-01677-2?ref=coios.me)

Paper

Distributional Cost-Effectiveness Analysis of Blood-Based Noninvasive Screening for MASLD among US Veterans: Assessing Health Equity Impact in the Era of Emerging Therapies

Authors

Chen W, Chang ST, Cheung RC, Chalfin DB, Sangha K, Kao SZ et al.

DOI

10.1007/s40273-026-01677-2

Type

Peer-reviewed article

Design

Distributional cost-effectiveness analysis (model-based, adapted published model), VHA perspective, 15 subgroups by race/ethnicity and Social Vulnerability Index quintile, $100,000/QALY opportunity-cost threshold, 2026 US dollars

Verdict

New finding

Driver

[Value in health](https://www.coios.me/d-health-economics/)